Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

2017/09/20 by Jonathan Webster, Jonathan A. Webster, Raoul Tibes +17
Biochemistry, Genetics and Molecular Biology · Medicine · #Acute Lymphoblastic Leukemia research #Acute Myeloid Leukemia Research #DNA Repair Mechanisms

paper · doi:10.1016/j.leukres.2017.09.005

openalex publication_date 2017/09/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Citations

• Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML